Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes
(reconstitutes) the powder with liquid to make it easier for users to treat patients with
severe hypoglycemia. The purpose of this study is to evaluate how much BIOD-961 absorbs into
the bloodstream, how much it raises glucose concentrations (the intended effect) and compare
to two glucagon products already on the market.